Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Arcellx Inc

Healthcare US ACLX

NoneUSD
0.00(0%)

Last update at 2026-06-18T21:33:41.328978Z

Day Range

--
LowHigh

52 Week Range

47.86115.13
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap6724.01M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-246.40499M
  • Revenue TTM22.29M
  • Revenue Per Share TTM0.40
  • Gross Profit TTM -135.32499M
  • Diluted EPS TTM-4.07

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -228.86500M -105.27900M -70.02700M -188.67900M -64.96900M
Minority interest - - - - -
Net income -228.93400M -107.34800M -70.69000M -186.09900M -63.92800M
Selling general administrative 117.76M 88.41M 66.35M 41.70M 18.14M
Selling and marketing expenses - - 0.00000M - -
Gross profit 15.61M 102.75M 110.32M - -
Reconciled depreciation 6.68M 5.19M 1.73M 1.32M 1.04M
Ebit -204.64700M -104.24900M -66.18500M -191.25900M -66.05900M
Ebitda -197.96900M -99.06100M -64.14500M -186.95900M -65.01800M
Depreciation and amortization 6.68M 5.19M 2.04M 4.30M 1.04M
Non operating income net other - - - - -
Operating income -253.08300M -137.57100M -89.88000M -191.25900M -65.01800M
Other operating expenses 275.37M 245.51M 200.20M 191.26M 65.02M
Interest expense 24.22M 1.03M 3.84M 1.72M 0.05M
Tax provision 0.07M 2.07M 0.66M - -
Interest income 24.22M 33.32M 19.38M 4.30M -
Net interest income 24.22M 32.29M 15.40M 2.58M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.07M 2.07M 0.66M -2.58000M -1.04100M
Total revenue 22.29M 107.94M 110.32M 0.00000M 0.00000M
Total operating expenses 268.69M 240.32M 200.20M 191.26M 65.02M
Cost of revenue 6.68M 5.19M 2.04M - -
Total other income expense net 24.22M 32.29M 19.85M 2.58M 0.05M
Discontinued operations - - - - -
Net income from continuing ops -228.93400M -107.34800M -129.52600M -188.67900M -64.96900M
Net income applicable to common shares - - - -188.67900M -64.96900M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 603.99M 711.33M 825.13M 313.82M 128.78M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 8.25M 11.94M 14.35M 12.03M 2.05M
Total liab 201.64M 256.54M 339.75M 108.86M 250.30M
Total stockholder equity 402.35M 454.79M 485.38M 204.95M -121.51500M
Deferred long term liab - - - 4.56M 3.17M
Other current liab 91.05M 56.72M 18.30M 11.68M 13.51M
Common stock 0.06M 0.05M 0.05M 0.04M 0.00100M
Capital stock 0.06M 0.05M 0.05M 0.04M 0.00100M
Retained earnings -725.76200M -496.82800M -389.48000M -318.79000M -130.11100M
Other liab - - - - 1.90M
Good will - - - - -
Other assets 442.40M - 11.77M 7.06M 5.66M
Cash 80.26M 105.68M 394.58M 64.18M 104.62M
Cash and equivalents - - - - -
Total current liabilities 104.20M 125.41M 118.24M 56.69M 14.85M
Current deferred revenue - 59.06M 50.53M - -
Net debt 16.00M -51.59900M -296.95800M 23.95M -104.61700M
Short term debt 7.58M 7.54M 46.78M 35.96M -
Short long term debt - - - - -
Short long term debt total 96.26M 54.08M 97.62M 88.13M -
Other stockholder equity 1127.21M 950.72M 874.26M 523.92M -20.27900M
Property plant equipment - - - - 10.32M
Total current assets 462.18M 599.31M 716.36M 266.86M 112.81M
Long term investments 69.72M 38.28M 27.17M - -
Net tangible assets - - - 204.95M -121.51500M
Short term investments 370.07M 481.70M 307.43M 190.66M 73.78M
Net receivables 3.60M - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 5.58M 2.10M 2.62M 9.05M 1.33M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.84M 0.85M 0.55M -0.22100M -0.02000M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 69.47M 3.50M -96.99500M 7.06M 5.66M
Deferred long term asset charges - - - - -
Non current assets total 141.81M 112.02M 97.00M 46.95M 15.97M
Capital lease obligations 51.92M 54.08M 97.62M 88.13M -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 88.62M -183.04500M -141.90700M -117.67400M -74.19300M
Change to liabilities - - - 7.42M 0.97M
Total cashflows from investing activities 86.30M -183.04500M -154.51200M -117.67400M -79.97600M
Net borrowings -0.23000M -39.84600M -29.39200M - -0.38700M
Total cash from financing activities 98.53M -24.08700M 279.16M 252.62M 118.45M
Change to operating activities - - - -2.96700M 1.75M
Net income -228.93400M -107.34800M -70.69000M -188.67900M -64.96900M
Change in cash -25.42700M -290.59900M 332.22M 35.65M -15.76300M
Begin period cash flow 108.31M 398.90M 66.68M 31.03M 46.80M
End period cash flow 82.88M 108.31M 398.90M 66.68M 31.03M
Total cash from operating activities -210.25800M -83.46700M 207.57M -99.30300M -54.23800M
Issuance of capital stock 131.56M 0.00000M 100.00M 259.83M 119.12M
Depreciation -1.76500M 5.19M 2.04M 1.32M 1.04M
Other cashflows from investing activities - - - - -
Dividends paid - - 271.40M - 119.12M
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 1.30M 1.16M 1.09M 0.00000M -0.02400M
Other cashflows from financing activities -38.42200M 15.76M 8.85M 2.47M 118.86M
Change to netincome - - - 83.60M 6.97M
Capital expenditures 2.33M 13.43M 21.43M 2.28M 5.78M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -57.49400M -30.77800M 225.43M 4.45M 2.72M
Stock based compensation 77.89M 61.09M 41.79M 21.54M 6.75M
Other non cash items 0.04M -11.61500M 9.01M 62.06M 0.21M
Free cash flow -212.58500M -96.90100M 186.15M -101.58000M -60.02100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ACLX
Arcellx Inc		 - -% - - 61.73 301.71 16.71 283.89 -6.5219
NVO
Novo Nordisk A/S		 1.15 2.51% 47.03 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.41 0.30% 468.20 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.50 1.06% 619.00 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize nito-cel and next-generation autologous and non-autologous CAR-T cell therapy products. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Arcellx Inc

800 Bridge Parkway, Redwood City, CA, United States, 94065

Key Executives

Name Title Year Born
Mr. Rami Elghandour Chairman, CEO & Pres 1979
Mr. Neeraj P. Teotia Chief Commercial Officer 1975
Dr. Christopher R. Heery M.D. Chief Medical Officer 1980
Ms. Michelle Lim Gilson Chief Financial Officer 1992
Mr. Michael Dombeck M.B.A. Chief Operating Officer NA
Mr. Narinderjeet Singh M.S. Chief Technical Officer 1972
Mr. David Tice Ph.D. Chief Scientific Officer 1971
Ms. Myesha Lacy VP of Investor Relations NA
Ms. Maryam Abdul-Kareem J.D., M.S. Gen. Counsel NA
Ms. Kate Aiken Chief People Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.